Daniel Rosenblum
Impact in
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
- Biomedical Engineering top 2%
- Nanoplatforms for cancer theranostics
- Graphene and Nanomaterials Applications
Papers in
- Immunology 10
- Immunotherapy and Immune Responses 4
- Co-authors
- Dan PeerWei TaoNitin JoshiJeffrey M. KarpSrinivas RamishettiNuphar VeigaRanit KedmiAnna Gutkin
- Journals
- Blood (3 papers)Clinical and Translational Science (3 papers)Journal of Controlled Release (3 papers)Nature Communications (2 papers)Journal of Clinical Investigation (2 papers)
- Partner nations
- United StatesIsraelUnited Kingdom
In The Last Decade
Daniel Rosenblum
35 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Biomaterials 1.1k
- Biomedical Engineering 1.1k
- Molecular Biology 1.8k
- Cancer Research 273
- Immunology 380
Countries citing papers authored by Daniel Rosenblum
This map shows the geographic impact of Daniel Rosenblum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Rosenblum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Rosenblum more than expected).
Fields of papers citing papers by Daniel Rosenblum
This network shows the impact of papers produced by Daniel Rosenblum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Rosenblum. The network helps show where Daniel Rosenblum may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Rosenblum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 36 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 1 | |
| 5 | 2022 | 8 | |
| 6 | 2021 | 41 | |
| 7 | CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy Hit paper breakdown → | 2020 | 430 |
| 8 | 2020 | 21 | |
| 9 | 2020 | 46 | |
| 10 | 2019 | 5 | |
| 11 | Progress and challenges towards targeted delivery of cancer therapeutics Hit paper breakdown → | 2018 | 1668 |
| 12 | 2018 | 249 | |
| 13 | 2016 | 18 | |
| 14 | 2015 | 125 | |
| 15 | 2014 | 231 | |
| 16 | 2013 | 61 | |
| 17 | 2013 | 12 | |
| 18 | 2012 | 7 | |
| 19 | 2004 | 10 | |
| 20 | 1998 | 6 |
About Daniel Rosenblum
Daniel Rosenblum is a scholar working on Business and International Management, Immunology, Public Health, Environmental and Occupational Health, Biomaterials and Molecular Biology, having authored 39 papers that have together received 3.3k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (10 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers), Advanced biosensing and bioanalysis techniques (5 papers), Health and Medical Research Impacts (4 papers), Nanoparticle-Based Drug Delivery (4 papers), Immunotherapy and Immune Responses (4 papers), CRISPR and Genetic Engineering (3 papers) and Alkaline Phosphatase Research Studies (3 papers). The work is most often cited by research in Biomaterials (1.1k citations), Biomedical Engineering (1.1k citations), Molecular Biology (1.8k citations), Cancer Research (273 citations) and Immunology (380 citations). Daniel Rosenblum has collaborated with scholars based in United States, Israel and United Kingdom. Frequent co-authors include Dan Peer, Wei Tao, Nitin Joshi, Jeffrey M. Karp, Srinivas Ramishetti, Nuphar Veiga, Ranit Kedmi, Anna Gutkin, Meir Goldsmith and Niels Dammes. Their work appears in journals such as Blood, Clinical and Translational Science, Journal of Controlled Release, Nature Communications and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.